Sara Cox, NP
Primary Care · West Point, MSNPI 1851765226
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations.
Across 87 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$281
- AstraZeneca$251
- Lilly USA, LLC$212
- Xeris Pharmaceuticals, Inc.$190
- Amgen$121
- Boehringer Ingelheim$65
- plus $395 from 10 others
What the payments were for
- Food & beverage$1,515100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $281 |
| AstraZeneca | 15 | $251 |
| Lilly USA, LLC | 11 | $212 |
| Xeris Pharmaceuticals, Inc. | 11 | $190 |
| Amgen | 8 | $121 |
| Boehringer Ingelheim | 4 | $65 |
| Bayer | 3 | $62 |
| Corcept Therapeutics | 3 | $56 |
| Dexcom, Inc. | 3 | $52 |
| Exact Sciences | 3 | $52 |
| GSK | 3 | $47 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Johnson & Johnson | 2 | $34 |
| Novartis | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
How this compares
$1,515 in reported general payments places this provider in the 70th percentile of 80 primary care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 148 | $196,604 |
| JardianceEmpagliflozin | 151 | $171,847 |
| EliquisApixaban | 94 | $95,597 |
| FarxigaDapagliflozin Propanediol | 87 | $78,746 |
| RybelsusSemaglutide | 44 | $69,160 |
| JanuviaSitagliptin Phosphate | 57 | $48,823 |
| TrulicityDulaglutide | 27 | $34,265 |
| LinzessLinaclotide | 50 | $32,753 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $29,157 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $25,781 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $18,384 |
| EntrestoSacubitril/Valsartan | 12 | $12,583 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $10,548 |
| TradjentaLinagliptin | 18 | $10,243 |
| Gvoke Hypopen 2-PackGlucagon | 12 | $7,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $281 | $265,763192 claims |
| Boehringer IngelheimJardiance, Tradjenta | $65 | $182,090169 claims |
| PfizerEliquis | $15 | $95,59794 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $251 | $92,449114 claims |
| Lilly USA, LLCTrulicity | $212 | $34,26527 claims |
| GSKTrelegy Ellipta | $47 | $18,38421 claims |
| NovartisEntresto | $21 | $12,58312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 80 primary care providers in Mississippi.
Other primary care in West Point
- Alisha McArthur WilkesRidgeland$17K
- Katrina BlackardSouthaven$14K
- Sarah HarringtonTupelo$11K
- Julie HarperNewhebron$10K
- Hannah IvisonJackson$10K
- Irene WilsonSouthaven$4K
- Mary EatonTupelo$4K
- Tanya SandersonTupelo$3K
- Amanda EllisKosciusko$3K
- Charity MilamSouthaven$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.